ALTME:EPA
TME Pharma NV
€0.081
arrow_downward
-4.14%(-0.0035) 1D
Jun 4, 5:35:04 PM GMT+2 · EUR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALTME...
Open
€0.08
High
€0.08
Low
€0.08
Mkt. cap
7.39M
Avg. vol.
164.50K
Volume
238.83K
52-wk high
€0.15
52-wk low
€0.05
EPS
-€0.03
No. of employees
0
Open
€0.08
High
€0.08
Low
€0.08
Mkt. cap
7.39M
Avg. vol.
164.50K
Volume
238.83K
52-wk high
€0.15
52-wk low
€0.05
EPS
-€0.03
No. of employees
0
News stories
From sources across the web
Simply Wall Street
·
32 minutes ago
MaxLinear Los Alamos Storage Offload Pushes Deeper Into AI Infrastructure
Foreign Policy Journal
·
34 minutes ago
Microsoft (NASDAQ: MSFT) To Launch Homegrown AI Model Suite At Annual Build Developer Conference
Stock Titan
·
10 minutes ago
InMed keeps Nasdaq spot after meeting $1 share-price rule
CBS News
·
2 hours ago
Dow soars nearly 900 points as Wall Street bets on Iran peace deal
Profile
TME Pharma, formerly NOXXON Pharma, is a biotechnology company founded in 1997 in Berlin, Germany which specialises on cancer treatment by targeting the tumor microenvironment. TME Pharma N.V. is listed on Euronext Growth, Paris and is a member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller.
TME Pharma develops drugs using technology yielding L-RNA molecules, which are of mirror-image configuration compared to naturally occurring D-RNA molecules. The company calls these agents Spiegelmers, from Spiegel, the German word for "mirror."
The L-RNA are resistant to the natural RNA nuclease enzymes. Wikipedia
About TME Pharma NV
AI content may include mistakes. Learn more